Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company's ELAD System consists of approximately four disposable ELAD C3A cell cartridges.
Industry, Sector and Symbol:
- Market Cap: $120.29 million
- Outstanding Shares: 42,207,000
- 50 Day Moving Avg: $3.52
- 200 Day Moving Avg: $4.46
- 52 Week Range: $2.55 - $8.38
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.10
- P/E Growth: -0.11
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.00 per share
- Price / Book: 1.43
- EBIDTA: ($42,650,000.00)
- Return on Equity: -51.74%
- Return on Assets: -48.40%
- Current Ratio: 15.00%
- Quick Ratio: 15.00%
- Average Volume: 127,456 shs.
- Beta: 5.42
- Short Ratio: 57.1
Frequently Asked Questions for Vital Therapies (NASDAQ:VTL)
What is Vital Therapies' stock symbol?
Vital Therapies trades on the NASDAQ under the ticker symbol "VTL."
How were Vital Therapies' earnings last quarter?
Vital Therapies Inc (NASDAQ:VTL) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.39) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.02. During the same quarter in the prior year, the company posted ($0.31) EPS. View Vital Therapies' Earnings History.
Where is Vital Therapies' stock going? Where will Vital Therapies' stock price be in 2017?
3 brokerages have issued 1 year price objectives for Vital Therapies' shares. Their predictions range from $6.00 to $10.00. On average, they expect Vital Therapies' share price to reach $8.00 in the next twelve months. View Analyst Ratings for Vital Therapies.
Who are some of Vital Therapies' key competitors?
Some companies that are related to Vital Therapies include Idera Pharmaceuticals (IDRA), Tabula Rasa HealthCare (TRHC), Corvus Pharmaceuticals (CRVS), Aratana Therapeutics (PETX), Abeona Therapeutics (ABEO), Ardelyx (ARDX), Corindus Vascular Robotics (CVRS), BioScrip (BIOS), Chimerix (CMRX), Corium International (CORI), Cascadian Therapeutics (CASC), Immune Design Corp (IMDZ), Cempra (CEMP), Fortress Biotech (FBIO), Stemline Therapeutics (STML), Viralytics Ltd Spon (VRACY), Osiris Therapeutics (OSIR) and Oxford Biomedica (OXBDF).
Who owns Vital Therapies stock?
Vital Therapies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (9.20%), Victory Capital Management Inc. (7.93%), Vanguard Group Inc. (2.63%), Geode Capital Management LLC (0.54%), Bank of New York Mellon Corp (0.27%) and TIAA CREF Investment Management LLC (0.24%). Company insiders that own Vital Therapies stock include Cheryl Cohen, Faheem Hasnain, Jean Jacques Bienaime, John Michael Dunn and Muneer A Satter. View Institutional Ownership Trends for Vital Therapies.
Who sold Vital Therapies stock? Who is selling Vital Therapies stock?
Who bought Vital Therapies stock? Who is buying Vital Therapies stock?
Vital Therapies' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc., SG Americas Securities LLC, Vanguard Group Inc., Geode Capital Management LLC, Bank of New York Mellon Corp and Goldman Sachs Group Inc.. Company insiders that have bought Vital Therapies stock in the last two years include Cheryl Cohen, Faheem Hasnain, Jean Jacques Bienaime, John Michael Dunn and Muneer A Satter. View Insider Buying and Selling for Vital Therapies.
How do I buy Vital Therapies stock?
Shares of Vital Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Vital Therapies stock cost?
One share of Vital Therapies stock can currently be purchased for approximately $2.85.
Earnings History for Vital Therapies (NASDAQ:VTL)Earnings History by Quarter for Vital Therapies (NASDAQ:VTL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Vital Therapies (NASDAQ:VTL)
Current Year EPS Consensus Estimate: $-1.67 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS
Dividend History for Vital Therapies (NASDAQ:VTL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vital Therapies (NASDAQ:VTL)
Insider Ownership Percentage: 29.88%Insider Trades by Quarter for Vital Therapies (NASDAQ:VTL)
Institutional Ownership Percentage: 26.68%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/27/2017||Muneer A Satter||Director||Buy||3,750,000||$4.00||$15,000,000.00|| |
|8/12/2016||Faheem Hasnain||Director||Buy||118,243||$5.92||$699,998.56|| |
|10/28/2015||Muneer A Satter||Director||Buy||400,000||$5.50||$2,200,000.00|| |
|10/26/2015||Cheryl Cohen||Director||Buy||3,500||$7.17||$25,095.00|| |
|10/26/2015||John Michael Dunn||General Counsel||Buy||9,385||$6.81||$63,911.85|| |
|9/10/2015||Jean Jacques Bienaime||Director||Buy||14,000||$3.08||$43,120.00|| |
|10/10/2014||Terence E Winters||CEO||Buy||1,360||$14.86||$20,209.60|| |
|10/8/2014||Duane Nash||Insider||Buy||100||$17.50||$1,750.00|| |
|10/8/2014||Lowell Sears||Director||Buy||1,429||$17.50||$25,007.50|| |
|6/3/2014||Muneer A Satter||Director||Buy||14,500||$13.16||$190,820.00|| |
|4/23/2014||Muneer A Satter||Director||Buy||360,966||$12.00||$4,331,592.00|| |
Headline Trends for Vital Therapies (NASDAQ:VTL)
Latest Headlines for Vital Therapies (NASDAQ:VTL)
|Vital Therapies Inc (VTL) Now Covered by Raymond James Financial, Inc.|
www.americanbankingnews.com - May 18 at 10:56 PM
|Edited Transcript of VTL earnings conference call or presentation 10-May-17 8:30pm GMT|
finance.yahoo.com - May 12 at 4:18 AM
|Investor Network: VITAL THERAPIES INC to Host Earnings Call|
finance.yahoo.com - May 11 at 3:19 AM
|Vital Therapies Inc (VTL) Upgraded at Zacks Investment Research|
www.americanbankingnews.com - May 10 at 10:36 PM
|Vital Therapies Inc (VTL) Announces Quarterly Earnings Results|
www.americanbankingnews.com - May 9 at 9:42 PM
|Vital Therapies Announces First Quarter 2017 Financial Results|
finance.yahoo.com - May 9 at 8:05 PM
|Vital Therapies reports 1Q loss|
marketbeat.com - May 9 at 7:28 PM
|Vital Therapies Inc (VTL) Scheduled to Post Quarterly Earnings on Tuesday|
www.americanbankingnews.com - May 7 at 7:28 AM
|Favorable Press Coverage Likely to Impact Vital Therapies (VTL) Stock Price|
www.americanbankingnews.com - May 3 at 8:08 PM
|Somewhat Critical Media Coverage Extremely Likely to Affect Vital Therapies (VTL) Stock Price|
www.americanbankingnews.com - April 30 at 8:58 AM
|-$0.37 Earnings Per Share Expected for Vital Therapies Inc (VTL) This Quarter|
www.americanbankingnews.com - April 29 at 1:14 AM
|Somewhat Favorable Media Coverage Unlikely to Impact Vital Therapies (VTL) Stock Price|
www.americanbankingnews.com - April 27 at 11:56 AM
|Vital Therapies (VTL) Getting Positive Media Coverage, Study Shows|
www.americanbankingnews.com - April 21 at 6:02 PM
|Vital Therapies Inc (VTL) Short Interest Down 9.2% in March|
www.americanbankingnews.com - April 15 at 5:56 PM
|Somewhat Positive Media Coverage Extremely Likely to Impact Vital Therapies (VTL) Share Price|
www.americanbankingnews.com - April 15 at 8:02 AM
|Vital Therapies Inc (VTL) Upgraded to Hold by Zacks Investment Research|
www.americanbankingnews.com - April 14 at 9:30 AM
|Vital Therapies Inc (VTL) Expected to Post Earnings of -$0.37 Per Share|
www.americanbankingnews.com - April 7 at 8:03 PM
|Vital Therapies Inc (VTL) Upgraded by Zacks Investment Research to Hold|
www.americanbankingnews.com - April 6 at 1:43 PM
|Muneer A. Satter Purchases 3,750,000 Shares of Vital Therapies Inc (VTL) Stock|
www.americanbankingnews.com - March 27 at 10:25 PM
|Vital Therapies Inc (VTL) Downgraded by Zacks Investment Research to Sell|
www.americanbankingnews.com - March 25 at 7:23 AM
|VITAL THERAPIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statement|
biz.yahoo.com - March 23 at 8:57 PM
|9:08 am Vital Therapies prices an underwritten public offering of 8.75 mln shares of common stock at $4.00/share for gross proceeds of about $35.0 mln|
finance.yahoo.com - March 23 at 7:27 AM
|VITAL THERAPIES INC Files SEC form 8-K, Other Events|
biz.yahoo.com - March 21 at 8:21 PM
|Edited Transcript of VTL earnings conference call or presentation 7-Mar-17 9:30pm GMT|
finance.yahoo.com - March 9 at 4:30 AM
|Vital Therapies Announces Fourth Quarter and Full Year 2016 Financial Results|
us.rd.yahoo.com - March 8 at 12:24 AM
|4:02 pm Vital Therapies misses by $0.01|
us.rd.yahoo.com - March 8 at 12:24 AM
|Q4 2016 Vital Therapies Inc Earnings Release - After Market Close|
biz.yahoo.com - March 7 at 8:19 AM
|Vital Therapies Announces Upcoming Fourth Quarter and Full Year 2016 Financial Results Conference Call With Webcast|
finance.yahoo.com - February 27 at 5:24 PM
|Edited Transcript of VTL earnings conference call or presentation 3-Nov-16 8:30pm GMT|
finance.yahoo.com - November 7 at 12:38 PM
|Q3 2016 Vital Therapies Inc Earnings Release - After Market Close|
biz.yahoo.com - November 3 at 12:39 PM
|Vital Therapies (VTL) Offers Corporate Update; Says 14 Subjects Enrolled in VTL-308|
www.streetinsider.com - September 15 at 8:09 PM
|VITAL THERAPIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - August 29 at 8:05 PM
|VITAL THERAPIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits|
biz.yahoo.com - August 15 at 10:14 AM
|Edited Transcript of VTL earnings conference call or presentation 2-Aug-16 8:30pm GMT|
finance.yahoo.com - August 3 at 11:33 AM
|Vital Therapies Announces Second Quarter Financial Results|
www.nasdaq.com - August 2 at 8:37 PM
|Q2 2016 Vital Therapies Inc Earnings Release - After Market Close|
biz.yahoo.com - August 2 at 7:22 AM
|Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast|
finance.yahoo.com - July 21 at 4:01 PM
|Looking for a Growth Stock? Why It is Time to Focus on Vital Therapies (VTL)|
finance.yahoo.com - June 14 at 9:44 AM
|VITAL THERAPIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of|
biz.yahoo.com - May 27 at 4:33 PM
|VITAL THERAPIES INC Financials|
finance.yahoo.com - May 17 at 1:04 PM
|Edited Transcript of VTL earnings conference call or presentation 10-May-16 8:30pm GMT|
finance.yahoo.com - May 12 at 5:03 PM
|VITAL THERAPIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib|
biz.yahoo.com - May 9 at 5:13 PM
|Q1 2016 Vital Therapies Inc Earnings Release - After Market Close|
biz.yahoo.com - May 9 at 7:07 AM
Vital Therapies (VTL) Chart for Sunday, May, 28, 2017